Why Pre-filled Syringes Are Becoming Central to Biologics Strategy
Welcome to Market Watch: Healthcare, Pharma & Biotech
Pre-filled syringes are no longer just a convenience format. They are becoming a strategic platform for injectable medicine.
According to Visiongain analysis, the global pre-filled syringes market is valued at US$9.21 billion in 2026 and projected to reach US$22.18 billion by 2036, growing at a CAGR of 9.2%.
Growth is driven by biologics and biosimilars, rising demand for self-administration, pressure on healthcare capacity, and continued innovation in drug delivery technologies.
For pharmaceutical companies, the market is no longer only about the syringe. It is about how injectable therapies are developed, commercialised, administered and scaled.
Visiongain top takeaways
A delivery format moving into the mainstream
Pre-filled syringes were once valued mainly for convenience. Compared with traditional vial-and-syringe systems, they reduced preparation time, improved dosing accuracy and lowered contamination risk.
Those advantages still matter in high-volume clinical settings, where sterility, dose consistency and workflow efficiency are critical. But demand is now being shaped by wider pressures.
Biologics are becoming more central to pharma pipelines. Chronic diseases require repeatable, long-term injectable treatment. Healthcare systems are moving more care into outpatient and home settings. Drug developers also need complex injectables to be easier to use, safer to administer and better suited to real-world patient routines.
This is why pre-filled syringes are evolving from a packaging decision to a strategic drug delivery choice.
Biologics are changing injectable delivery
Biologics are changing what pharma companies need from injectable delivery.
These therapies are often higher-value, more sensitive and more complex to administer than many traditional small-molecule medicines. They need accurate dosing, careful handling and formats that protect product integrity from manufacture to administration.
As some biologics move towards higher concentrations and lower injection volumes, container compatibility, glide performance, needle design and patient comfort are becoming more important.
For biologics and biosimilars used in immunology, oncology, metabolic disease and rare conditions, the delivery system can influence uptake, adherence, clinical workflow and commercial positioning.
Recent activity shows the shift. In April 2025, the US FDA approved a prefilled syringe version of argenx’s VYVGART Hytrulo, enabling at-home self-administration for eligible patients. GLP-1 growth is also increasing scrutiny on formats that can support repeat use, patient confidence and high-volume demand.
Patient-led care is becoming a market driver
Patient-centric care is often discussed in broad terms. In pre-filled syringes, it is practical: fewer preparation steps, fewer dosing errors, shorter administration time and a better fit for self-injection or assisted home care.
That matters in chronic conditions where patients need regular treatment over long periods. Diabetes, rheumatoid arthritis, autoimmune disorders and some oncology-related supportive care settings all require reliable, repeatable injection formats.
For healthcare systems, ready-to-administer syringes can reduce clinician preparation time, lower wastage, improve workflow and support treatment outside high-cost clinical environments.
The shift to home care does not remove complexity. It redistributes complexity into device design, patient training, packaging clarity, safety systems and support infrastructure. Human factors, needle safety, ergonomic design and autoinjector compatibility are therefore becoming more important.
Innovation is moving beyond glass and plastic
Material choice still matters. Glass offers strong barrier performance, transparency and established pharmaceutical compatibility. Polymer-based syringes, including COP and COC formats, are gaining attention where break resistance, lower weight, design flexibility and compatibility with sensitive formulations are priorities.
But innovation is no longer limited to the barrel material.
Safety pre-filled syringes, dual-chamber formats, customised drug-device combinations, connected devices and large-volume delivery platforms are changing buyer expectations. Dual-chamber designs suit therapies that need separate components until administration, while connected systems may support adherence monitoring and remote patient support.
Regulatory demands are also rising. As pre-filled syringes move deeper into drug-device combination strategy, companies need to manage usability, component performance, quality documentation and product-specific risk earlier in development.
Visiongain identifies Becton Dickinson, Gerresheimer, SCHOTT AG, Stevanato Group, West Pharmaceutical Services, Vetter, Terumo, Nipro, AptarGroup, Catalent, and Credence MedSystems as active companies in the market, spanning containment, components, fill-finish, device platforms, and drug-device delivery systems.
Visiongain insight: Innovation is moving from materials to systems, where containment, usability, safety, regulation and supply reliability increasingly need to work together.
Supply chains are becoming part of the strategy
Pre-filled syringes bring together pharma, medical devices, materials science and sterile manufacturing. That makes supply reliability strategically important.
Pharmaceutical-grade glass, specialist polymers, elastomeric components, needles, safety systems and fill-finish capacity all need to work together. For biologics, the margin for error is limited. Compatibility, sterility, stability and regulatory compliance determine whether a product can be manufactured, approved and supplied with confidence.
This favours suppliers with proven capacity, regional manufacturing strength and close technical relationships with pharma companies. It also raises barriers to entry. As drug-device combinations become more sophisticated, buyers will look for partners that can support early development, validation, scale-up and lifecycle management.
Capacity is now part of the competitive picture. Growth in biologics, biosimilars, vaccines and GLP-1 therapies is increasing demand for sterile fill-finish, device assembly and flexible supply models.
For CMOs and CDMOs, the opportunity is growing. Pharma companies are under pressure to bring therapies to market faster while managing capital spend. Outsourced fill-finish and device assembly capabilities are becoming a more important part of injectable drug strategy.
Market outlook
The pre-filled syringes market is entering a more execution-driven phase of growth.
Demand is being supported by biologics and biosimilars, chronic disease treatment, self-administration and pressure on healthcare capacity. But growth will depend on more than demand. Suppliers will need to meet higher expectations around drug compatibility, patient usability, regulatory readiness and supply reliability.
Applications such as diabetes, rheumatoid arthritis, oncology, vaccines and anaphylaxis will continue to shape demand. However, biologics, complex injectables and high-volume metabolic therapies are likely to drive many of the tougher requirements.
The next phase of the market will therefore be shaped by execution as much as opportunity. As injectable therapies become more complex and care moves closer to the patient, the strongest companies will be those that can connect product design, usability, regulatory confidence and dependable supply.
From Visiongain
Visiongain’s Pre-filled Syringes Market Report 2026–2036 examines how biologics demand, self-administration, drug-device innovation, fill-finish capacity and supply chain resilience are reshaping the global injectable drug delivery market.
The report provides revenue forecasts by material, design, application, end user and region, alongside analysis of competitive positioning, supply chain capability, drug-device innovation and fill-finish constraints.
To identify the segments, regions and companies best positioned for growth, request sample pages.
Latest Reports
Detailed market forecasts, competitive analysis, and sector insights help R&D, manufacturing, supply chain, and commercial teams make decisions.
Press & Media Enquiries
For commentary, data requests or interview enquiries, please contact: press@visiongain.com
